CN1187330C - 吲哚衍生物、制备它们的方法、含有它们的药用组合物和它们的医疗应用 - Google Patents

吲哚衍生物、制备它们的方法、含有它们的药用组合物和它们的医疗应用 Download PDF

Info

Publication number
CN1187330C
CN1187330C CNB00811515XA CN00811515A CN1187330C CN 1187330 C CN1187330 C CN 1187330C CN B00811515X A CNB00811515X A CN B00811515XA CN 00811515 A CN00811515 A CN 00811515A CN 1187330 C CN1187330 C CN 1187330C
Authority
CN
China
Prior art keywords
pharmaceutically acceptable
compound
acceptable salt
hydrogen
propanamine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB00811515XA
Other languages
English (en)
Chinese (zh)
Other versions
CN1368960A (zh
Inventor
J·M·本特利
J·R·A·罗菲
J·E·P·达维森
H·L·曼塞尔
R·J·哈姆利恩
I·A·克利菲
D·R·亚当斯
N·J·蒙克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ligand UK Research Ltd
Original Assignee
Vernalis Research Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vernalis Research Ltd filed Critical Vernalis Research Ltd
Publication of CN1368960A publication Critical patent/CN1368960A/zh
Application granted granted Critical
Publication of CN1187330C publication Critical patent/CN1187330C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/94—[b, c]- or [b, d]-condensed containing carbocyclic rings other than six-membered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
CNB00811515XA 1999-08-11 2000-08-04 吲哚衍生物、制备它们的方法、含有它们的药用组合物和它们的医疗应用 Expired - Fee Related CN1187330C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9918962.3A GB9918962D0 (en) 1999-08-11 1999-08-11 Chemical compounds xxii
GB9918962.3 1999-08-11

Publications (2)

Publication Number Publication Date
CN1368960A CN1368960A (zh) 2002-09-11
CN1187330C true CN1187330C (zh) 2005-02-02

Family

ID=10858982

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB00811515XA Expired - Fee Related CN1187330C (zh) 1999-08-11 2000-08-04 吲哚衍生物、制备它们的方法、含有它们的药用组合物和它们的医疗应用

Country Status (21)

Country Link
US (1) US6706750B1 (OSRAM)
EP (1) EP1202965B1 (OSRAM)
JP (1) JP2003507367A (OSRAM)
KR (1) KR100740172B1 (OSRAM)
CN (1) CN1187330C (OSRAM)
AR (1) AR037222A1 (OSRAM)
AT (1) ATE279392T1 (OSRAM)
AU (1) AU773337B2 (OSRAM)
BR (1) BR0013307A (OSRAM)
CA (1) CA2377646A1 (OSRAM)
DE (1) DE60014918T2 (OSRAM)
DK (1) DK1202965T3 (OSRAM)
ES (1) ES2228588T3 (OSRAM)
GB (1) GB9918962D0 (OSRAM)
MX (1) MXPA01013235A (OSRAM)
PE (1) PE20010574A1 (OSRAM)
PT (1) PT1202965E (OSRAM)
TR (1) TR200200352T2 (OSRAM)
UY (1) UY26291A1 (OSRAM)
WO (1) WO2001012603A1 (OSRAM)
ZA (1) ZA200110217B (OSRAM)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9902047D0 (en) * 1999-01-29 1999-03-17 Cerebrus Ltd Chemical compounds XI
GB9918965D0 (en) * 1999-08-11 1999-10-13 Cerebrus Ltd Chemical compounds xxi
US20040077605A1 (en) * 2001-06-20 2004-04-22 Salvati Mark E. Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
EP1854798A3 (en) * 2000-09-19 2007-11-28 Bristol-Myers Squibb Company Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
ATE403647T1 (de) * 2000-10-16 2008-08-15 Hoffmann La Roche Indolinderivate und deren verwendung als 5-ht2 rezeptor liganden
ATE406371T1 (de) * 2000-11-02 2008-09-15 Us Gov Health & Human Serv Wirkstoffe für die verminderung von amyloid precursor protein und die behandlung von schwachsinn, und deren verfahren der verwendung
US6777407B2 (en) 2000-11-03 2004-08-17 Wyeth Cyclopenta[b][1,4]diazepino[6,7,1-hi]indoles and derivatives
AR031199A1 (es) 2000-11-03 2003-09-10 Wyeth Corp Ciclohepta/b//1,4/diacepino/6,7,1-hi/indoles y derivados
AR031200A1 (es) 2000-11-03 2003-09-10 Wyeth Corp Cicloocta [b] [1,4] diazepino [6,7,1-hi] indoles y derivados
SE0004245D0 (sv) 2000-11-20 2000-11-20 Pharmacia Ab Novel compounds and their use
JP4204315B2 (ja) 2000-11-20 2009-01-07 ビオヴィトルム・アクチボラゲット（プブリクト） セロトニン５−ｈｔ２レセプターのアンタゴニストとしてのピペラジニルピラジン化合物
US20040087548A1 (en) 2001-02-27 2004-05-06 Salvati Mark E. Fused cyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
AU2002364082A1 (en) * 2001-12-19 2003-07-09 Bristol-Myers Squibb Company Fused heterocyclic compounds and analogs thereof: modulators of nuclear hormone receptor function
TWI312781B (en) 2002-04-25 2009-08-01 [1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents
TW200307682A (en) 2002-04-25 2003-12-16 Wyeth Corp 1,2,3,4,7,8-Hexahydro-6H-[1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents
TW200307540A (en) 2002-04-25 2003-12-16 Wyeth Corp [1, 4]Diazocino[7, 8, 1-hi] indole derivatives as antipsychotic and antiobesity agents
MXPA04012711A (es) 2002-06-19 2005-03-23 Biovitrum Ab Nuevos compuestos, su uso y preparacion.
WO2004063156A1 (en) * 2003-01-08 2004-07-29 Biovitrum Ab Novel indole derivates as fabp-4 inhibitors
CL2004000826A1 (es) 2003-04-25 2005-03-04 Pfizer Uso de un agonista para el receptor 5-ht2c para preparar un medicamento util en el tratamiento de la incontinencia urinaria provocada por estres, con la condicion de que el agonista no sea 1-[6-cloro-5-(trifluorometil)-2-piridinil]piperazina (org-129
GB0314967D0 (en) * 2003-06-26 2003-07-30 Hoffmann La Roche Piperazine derivatives
US7767689B2 (en) * 2004-03-15 2010-08-03 Ptc Therapeutics, Inc. Carboline derivatives useful in the treatment of cancer
ES2401335T3 (es) 2004-03-15 2013-04-18 Ptc Therapeutics, Inc. Derivados de carbolina útiles en la inhibición de la angiogénesis
US8076352B2 (en) * 2004-03-15 2011-12-13 Ptc Therapeutics, Inc. Administration of carboline derivatives useful in the treatment of cancer and other diseases
WO2005089752A2 (en) * 2004-03-15 2005-09-29 Ptc Therapeutics, Inc. Tetra-cyclic carboline derivatives for inhibiting angiogenesis
US8076353B2 (en) * 2004-03-15 2011-12-13 Ptc Therapeutics, Inc. Inhibition of VEGF translation
WO2006012310A2 (en) * 2004-06-25 2006-02-02 Genzyme Corporation Carbazole derivatives for treating polycystic kidney disease
EP2248524A3 (en) 2004-08-25 2011-03-09 Takeda Pharmaceutical Company Limited Preventives/remedies for stress urinary incontinence and method of screening the same
GT200500317A (es) 2004-11-05 2006-10-27 Proceso para preparar compuestos de quinolina y productos obtenidos de los mismos
CN101103000B (zh) * 2004-11-23 2012-06-27 Ptc医疗公司 用于抑制vegf生成的咔唑、咔啉和吲哚衍生物
EP1824821A2 (en) 2004-11-23 2007-08-29 PTC Therapeutics, Inc. Carbazole, carboline and indole derivatives useful in the inhibition of vegf production
GB2422828A (en) * 2005-02-03 2006-08-09 Hunter Fleming Ltd Tricyclic cytoprotective compounds comprising an indole residue
AR054849A1 (es) 2005-07-26 2007-07-18 Wyeth Corp Diazepinoquinolinas, sintesis de las mismas, e intermediarios para obtenerlas
WO2007132841A1 (ja) 2006-05-16 2007-11-22 Takeda Pharmaceutical Company Limited 縮合複素環化合物およびその用途
JP5520051B2 (ja) 2007-11-15 2014-06-11 武田薬品工業株式会社 縮合ピリジン誘導体およびその用途
WO2011071136A1 (ja) 2009-12-11 2011-06-16 アステラス製薬株式会社 線維筋痛症治療剤
WO2015066344A1 (en) 2013-11-01 2015-05-07 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists and compositions and methods of use
WO2019131902A1 (ja) 2017-12-27 2019-07-04 武田薬品工業株式会社 腹圧性尿失禁および便失禁の治療薬
US20250051276A1 (en) * 2021-12-15 2025-02-13 Delix Therapeutics, Inc. Aryloxy psychoplastogens and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2541211A (en) 1948-10-15 1951-02-13 Searle & Co Tertiary-aminoalkyl-tetrahydrocarbazoles
US2687414A (en) * 1948-11-26 1954-08-24 Searle & Co Method for producing aromatic aminoalkyl amines
DE930988C (de) * 1953-01-01 1955-07-28 Bayer Ag Verfahren zur Herstellung von basisch alkylierten Tetrahydrocarbazolen oder Indolen
US3133930A (en) * 1961-08-15 1964-05-19 Ciba Geigy Corp Ester and amide derivatives of thieno-[3, 2-b] indole 3-carboxylic acids
US3151120A (en) * 1961-08-15 1964-09-29 Ciba Geigy Corp Thieno [3, 2-b] indole esters and amides
US3329571A (en) * 1961-10-24 1967-07-04 American Home Prod Methods for treating depression
NL284655A (OSRAM) 1961-10-24
US3142678A (en) * 1962-01-09 1964-07-28 American Home Prod Amino substituted penthienoindoles
TW334423B (en) * 1993-10-22 1998-06-21 Hoffmann La Roche Tricyclic 1-aminoethylpyrrole-derivatives
TW270114B (OSRAM) 1993-10-22 1996-02-11 Hoffmann La Roche
TW403738B (en) * 1994-08-12 2000-09-01 Hoffmann La Roche Tricyclic pyrazole derivatives
WO1998030548A1 (en) * 1997-01-13 1998-07-16 Yamanouchi Pharmaceutical Co., Ltd. 5-HT2c RECEPTOR AGONISTS AND AMINOALKYLINDAZOLE DERIVATIVES

Also Published As

Publication number Publication date
KR20020015078A (ko) 2002-02-27
ATE279392T1 (de) 2004-10-15
WO2001012603A1 (en) 2001-02-22
US6706750B1 (en) 2004-03-16
GB9918962D0 (en) 1999-10-13
PT1202965E (pt) 2005-01-31
EP1202965A1 (en) 2002-05-08
AU773337B2 (en) 2004-05-20
ES2228588T3 (es) 2005-04-16
ZA200110217B (en) 2002-12-12
UY26291A1 (es) 2001-03-16
CA2377646A1 (en) 2001-02-22
DE60014918T2 (de) 2005-10-13
DE60014918D1 (de) 2004-11-18
DK1202965T3 (da) 2005-02-14
MXPA01013235A (es) 2002-06-04
TR200200352T2 (OSRAM) 2002-06-21
JP2003507367A (ja) 2003-02-25
AR037222A1 (es) 2004-11-03
KR100740172B1 (ko) 2007-07-16
EP1202965B1 (en) 2004-10-13
AU6455500A (en) 2001-03-13
CN1368960A (zh) 2002-09-11
PE20010574A1 (es) 2001-05-21
BR0013307A (pt) 2002-05-28

Similar Documents

Publication Publication Date Title
CN1187330C (zh) 吲哚衍生物、制备它们的方法、含有它们的药用组合物和它们的医疗应用
CN1165537C (zh) 作为5-ht2c兴奋剂的吡咯并吲哚、吡啶并吲哚和氮杂�并吲哚
CN1289499C (zh) 吡嗪并(氮杂)吲哚衍生物
CN1250549C (zh) 吲哚衍生物及其作为5－ht2b和5－ht2c受体配体的应用
CN1277828C (zh) 哌嗪衍生物
CN1167681C (zh) 稠合二氢吲哚衍生物及其作为5ht特别是5ht2c受体配体的用途
CN100351236C (zh) 用作5－羟色胺－6配体的1－杂环基烷基－3－磺酰基－吲哚衍生物，其制备方法和用途
CN1281608C (zh) 新氮杂－吲哚基衍生物
CN1308311C (zh) 新型吡啶－和喹啉－衍生物
US6479534B1 (en) Indoline derivatives and method of treating obesity
CZ165693A3 (en) 5-heteroindole derivatives, process of their preparation, intermediates of such process and the use of these compounds
CN1620438A (zh) 用作cbi拮抗剂的5,6－二芳基－吡嗪－2－酰胺衍生物
CN1491225A (zh) 三杂环化合物和包括其作为活性组分的药物
CN101035528A (zh) 治疗丙型肝炎病毒感染的咔唑和环戊二烯并吲哚衍生物
CN1245405C (zh) 哌嗪衍生物
CN87103504A (zh) 杂环羧酰胺
CN1798744A (zh) 作为nmda/nr2b拮抗剂的3－氟－哌啶化合物
CN1285594C (zh) 催产素兴奋剂
CN1926098A (zh) 新的脲衍生物及其医药应用
CN1293061C (zh) 新的3－氨基－1－苯基－1h－[1,2,4]三唑的支链取代氨基衍生物、其制备方法和含有它们的药物组合物
CN1826346A (zh) 作为5－羟色胺－6配位体的n－磺酰基杂环吡咯基烷基胺化合物
CN1705659A (zh) 大电导钙激活k通道开启剂
CN1555355A (zh) 被取代的4-氨基环己醇衍生物
CN1882546A (zh) 用于治疗神经病疼痛的吡啶－4－基胺化合物
CN1094126C (zh) 吡咯并吖庚因化合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee